Skip to main content

Table 2 Patient characteristics at the 12-month follow-up visit

From: 1-year prospective real life monitoring of asthma control and quality of life in Italy

  Total Controlled Partly controlled Uncontrolled Overall p-value
Number of patients, n (%) 739 598 (80.9) 87 (11.8) 54 (7.3)  
Smoking habits, n (%) (1)      0.437
  Current smokers 136 (18.4) 113 (18.9) 14 (16.1) 9 (16.7)  
  Non-smokers 468 (63.3) 384 (64.2) 50 (57.5) 34 (63.0)  
  Ex-smokers (2) 128 (17.3) 97 (16.2) 21 (24.1) 10 (18.5)  
  Not available 7 (0.9) 4 (0.7) 2 (2.3) 1 (1.9)  
Improvement of 3 points in ACT score, n (%) 642 (86.9) 572 (95.7) 55 (63.2) 15 (27.8) <0.001(3)
Quality of life, n 733 593 86 54  
  EQ-5D(4) score, mean (SD) 0.87 (0.19) 0.91 (0.13) 0.71 (0.23) 0.62 (0.30) <0.001(5)
  EQ-5D(4) VAS score, mean (SD) 80.0 (13.6) 83.8 (10.2) 67.2 (12.1) 58.9 (16.0) <0.001(6)
Antiasthmatic therapy, n (%) (7)      
  No therapy 59 (8.0) 55 (9.2) 3 (3.5) 1 (1.9) -
  ICS /LABA 602 (81.5) 484 (80.9) 72 (82.8) 46 (85.2) -
  LTRA 237 (32.1) 165 (27.6) 42 (48.3) 30 (55.6) -
  ICS 71 (9.6) 55 (9.2) 7 (8.1) 9 (16.7) -
  Short-acting β2agonist 42 (5.7) 21 (3.5) 13 (14.9) 8 (14.8) -
  1. (1) Smoking habits was reported only at the cross-sectional phase visit; (2) Patients who stopped smoking since at least one year; (3) Bonferroni’s corrected p < 0.001 for all comparisons; (4) EQ-5D: EuroQoL-5D questionnaire; (5) Bonferroni’s corrected p < 0.001 patients with controlled asthma vs. patients with partly controlled and uncontrolled asthma; Bonferroni’s corrected p = 0.060 patients with partly controlled asthma vs. patients with uncontrolled asthma; (6) Bonferroni’s corrected p < 0.001 patients with controlled asthma vs. patients with partly controlled and uncontrolled asthma; Bonferroni’s corrected p = 0.004 patients with partly controlled asthma vs. patients with uncontrolled asthma; (7) Data are percentage of patients in each category of asthma control reporting therapies for at least 5 consecutive days in the last 3 months; patients could have more than one pharmacologic class therapy; ICS: inhaled corticosteroids; LABA: long-acting β2 agonist; LTRA: leukotriene receptor antagonists.